Bio-Techne shareholders approve Merck KGaA deal
- Bio-Techne (NASDAQ:TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany.
- The approval adopts the definitive merger agreement between Bio-Techne and Merck KGaA.
- Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to remaining approvals and closing conditions.
Bio-Techne (NASDAQ:TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026.
The shareholder vote adopts the definitive merger agreement, which Bio-Techne said will combine two life science businesses across research, development, testing, and commercial manufacturing activities.
Bio-Techne said final voting results from the special meeting will be disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission.
The Hart-Scott-Rodino antitrust waiting period for the transaction expired on September 18, 2026, removing a key U.S. regulatory review step.
Bio-Techne continues to expect the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals and customary closing conditions.
Frequently asked questions
More from United States
Gray Media reports $972 million Q3 revenue as political advertising surges
VEON boosts 2026 outlook as Q3 revenue grows 17.2% to $1.31 billion
Utz Brands misses Q3 estimates as revenue falls 2.3% and losses widen
Elanco raises 2026 outlook as Q3 revenue grows 11% to $1.265 billion
Algonquin Power reports $57.6 million Q3 net earnings
TDS reveals lower Q3 earnings, adds $250 million buyback
